Funding Will Support Development of Biomodex Products for Interventional Cardiology
June 7, 2018—Biomodex announced that the company has raised an additional $15 million in Series A funding that it intends to use to develop new products in the interventional cardiology space and enable the opening of a new manufacturing facility outside of Boston, Massachusetts. Biomodex is a medical device company based in Paris, France, and Boston, that uses three-dimensional (3D) printing technology to develop patient-specific synthetic organs for preoperative planning.
According to the company, Biomodex's technology enables the 3D printing of organs based on medical imaging, such as a CT scan or echocardiography. By combining 3D printing with the technology, the company is able to produce the biomechanics of the organ and surrounding tissue, mimicking the patient-specific biomechanical properties and behavior with a quick turnaround time. The solution has primarily been used for interventional neuroradiology applications.
The funding round brings total financing to more than $18.5 million. The new financing was led by Idinvest Partners and InnovAllianz with participation of pre-existing investors, LBO France and Inserm Transfert Initiative.